| Authors: |
Malhotra J; Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey. Electronic address: jm1940@cinj.rutgers.edu., Nikolinakos P; Hematology and Medical Oncology, University Cancer & Blood Center, Athens, Georgia., Leal T; Hematology-Oncology, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Lehman J; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Morgensztern D; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri., Patel JD; Department of Medicine (Oncology), Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Wrangle JM; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina., Curigliano G; Division of Early Drug Development for Innovative Therapy, Istituto Europeo di Oncologia, IRCCS, Milano, Italy; Department of Oncology and Haematology, University of Milano, Milano, Italy., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Timone, Aix Marseille University, Marseille, France., Johnson ML; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, Tennessee., Ready N; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina., Robinet G; Service de Pneumologie, CHU de Brest-Hôpital Morvan, Brest, France., Lally S; AbbVie Stemcentrx, South San Francisco, California., Maag D; AbbVie Inc., Chicago, Illinois., Valenzuela R; AbbVie Stemcentrx, South San Francisco, California., Blot V; AbbVie Inc., Chicago, Illinois., Besse B; Gustave Roussy, Villejuif, France; Espace Technologique, Paris-Saclay University, Saint-Aubin, France. |
